Developing life-changing genetic medicines
Neurogene (neurogene.com) scores 76 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 48th percentile of 13187 Healthcare brands.
Neurogene is a biotechnology company focused on developing gene therapies for rare neurological disorders. Its mission is to transform devastating neurological diseases into treatable conditions, improving outcomes for patients and families affected by these rare diseases. The company's platform technology is applied to a pipeline that includes a therapy for Rett syndrome. Neurogene emphasizes patient-centered insight and scientific innovation in its approach to genetic medicine, aiming to serve both affected communities and the broader medical and scientific community working on rare neurological conditions.
| Brand Name | Neurogene |
|---|---|
| Domain | neurogene.com |
| Industry | Healthcare |
| Main Competitors | Taysha Gene Therapies, Ultragenyx Pharmaceutical (79/100), REGENXBIO (74/100), Solid Biosciences (77/100), Passage Bio, Sarepta Therapeutics (83/100), uniQure (81/100) |
Moz Domain Authority 34/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #2,325,829 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "At Neurogene, our mission is to turn devastating neurological diseases into treatable conditions, to improve the lives of patients and families impacted by these rare diseases." (No meta description. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:image, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on Facebook, LinkedIn, X (Twitter), Instagram, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Neurogene?", Claude could identify the brand as of October 2026. Neurogene is a clinical-stage biotechnology company developing gene therapies for severe genetic neurological diseases, including Rett syndrome and CDKL5 deficiency disorder. It was founded by Rachel McMinn and uses its proprietary EXACT gene therapy technology to try to improve Best known for developing AAV-based gene therapies for Rett syndrome and CDKL5 deficiency disorder.
When asked "Best brands similar to Neurogene?", Claude would recommend Neurogene as of October 2026. It's a notable name in the rare neurological disease gene therapy space, so I'd mention it if someone asked about companies working on gene therapies for conditions like Rett syndrome.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Neurogene's main competitors in Healthcare: Ultragenyx Pharmaceutical (79/100), REGENXBIO (74/100), Solid Biosciences (77/100), Sarepta Therapeutics (83/100), uniQure (81/100).
Sources: Brand Analyzer scan
Neurogene has limited AI-search visibility, scoring 26/100 on Brand Analyzer's AI visibility composite (visibility 17, trust 22, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Neurogene official site
Neurogene scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Neurogene official site
Neurogene is a biotechnology company that develops gene therapies aimed at treating rare, devastating neurological diseases. It uses a proprietary platform technology to design purpose-built therapies, with a pipeline that includes a program targeting Rett syndrome. The company positions itself as mission-driven, combining scientific innovation with patient-centered insight to address high unmet medical needs in genetic neurological disorders.
Sources: Neurogene official site
Neurogene develops gene therapies intended to convert devastating neurological diseases into treatable conditions. It applies a differentiated platform technology to create purpose-built treatments for rare neurological disorders, with a focused pipeline that includes therapy development for Rett syndrome. The company works to translate scientific research into clinical applications that could improve outcomes for patients and families affected by these rare diseases.
Sources: Neurogene official site
Neurogene can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Neurogene official site
Neurogene offers gene therapy products in development for rare neurological disorders, with a pipeline that includes a program targeting Rett syndrome. These are built on the company's proprietary platform technology designed to create purpose-built treatments for specific genetic neurological conditions.
Sources: Neurogene official site
Neurogene is known for its focus on gene therapy development for rare neurological diseases, particularly its pipeline program targeting Rett syndrome. The company is recognized within the genetic medicine field for combining a proprietary platform technology with patient-centered research to address diseases with significant unmet medical need.
Sources: Neurogene official site
Neurogene's work is intended for patients and families affected by rare, devastating neurological diseases, such as those with Rett syndrome. Additionally, the medical and scientific community focused on genetic medicine engages with Neurogene's research and development efforts.
Sources: Neurogene official site
Neurogene scores 26/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Neurogene has a weak AI-visibility profile at 26/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (17/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #2,325,829 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 34/100 and thin schema.org structured data. In a live check, Claude could already identify Neurogene from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Neurogene: netDoktor (76/100), NEOCUTIS (76/100), Nevro (76/100), NewSpring (76/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.